NSCLC, metastatic 1
Invited discussant LBA43 and abstract 1201O
Date
09 Oct 2016Session
NSCLC, metastatic 1Presenters
Pasi JänneAuthors
P.A. JänneAuthor affiliations
- Thoracic Oncology, Dana-Farber Cancer Institute, 02215 - Boston/US
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3732 - Ceritinib vs chemotherapy (CT) in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib (CRZ): Results from the confirmatory phase 3 ASCEND-5 study
Presenter: Giorgio Scagliotti
Session: NSCLC, metastatic 1
Resources:
Abstract
Slides
2356 - Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
Presenter: Enriqueta Felip
Session: NSCLC, metastatic 1
Resources:
Abstract
Slides
Invited discussant LBA42_PR and abstract 1208O
Presenter: Egbert Smit
Session: NSCLC, metastatic 1
Resources:
Slides
2988 - Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7)
Presenter: Luis Paz-Ares
Session: NSCLC, metastatic 1
Resources:
Abstract
Slides
3919 - Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis
Presenter: Jean-Charles Soria
Session: NSCLC, metastatic 1
Resources:
Abstract
Slides